Holen Sie sich die Stockscreener-App
0.7799
8.35%
-0.0488
Schlusskurs vom Vortag:
$0.8287
Offen:
$0.83
24-Stunden-Volumen:
218.01K
Relative Volume:
0.87
Marktkapitalisierung:
$1.40M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-3.86M
KGV:
-0.0321
EPS:
-24.3033
Netto-Cashflow:
$-4.78M
1W Leistung:
-33.38%
1M Leistung:
-32.19%
6M Leistung:
-98.14%
1J Leistung:
-98.32%
1-Tages-Spanne:
$0.7463
$0.8396
1-Wochen-Bereich:
$0.7504
$1.1798
52-Wochen-Spanne:
$0.7504
$52.40
Clearmind Medicine Inc Stock (CMND) Company Profile
Firmenname
Clearmind Medicine Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare CMND vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
0.7799 | 1.49M | 0 | -3.86M | -4.78M | -24.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.75 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.28 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
703.21 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.43 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.37 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Clearmind Medicine Inc Aktie (CMND) Neueste Nachrichten
Clearmind files Hong Kong patent for depression treatment combo By Investing.com - Investing.com Canada
Clearmind files Hong Kong patent for depression treatment combo - Investing.com
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy - Bitget
Clearmind Medicine Inc. Files Patent for Innovative Non-Hallucinogenic Therapy Combining MEAI and PEA to Address Major Depressive Disorder - Quiver Quantitative
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Bitget
SciSparc Ltd. Advances Collaboration with NeuroThera Labs Inc. and Clearmind Medicine Inc. for Novel Combination Therapy Targeting Obesity and MASLD. - Quiver Quantitative
SciSparc: NeuroThera Labs Announces Publication of - GlobeNewswire
Clearmind advances enrollment in alcohol disorder drug trial - Investing.com India
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results - Bitget
Clearmind advances enrollment in alcohol disorder drug trial By Investing.com - Investing.com Nigeria
NeuroThera and Clearmind Advance Patent for Obesity and Liver Disease Therapy - TipRanks
Clearmind Medicine Inc. Advances Enrollment for Third Cohort in Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder - Quiver Quantitative
Non-hallucinogenic AUD drug CMND-100 moves into third trial cohort - Stock Titan
NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - TheNewswire
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Bitget
Clearmind files patent for obesity, liver disease treatment combo - Investing.com Nigeria
Clearmind files patent for obesity, liver disease treatment combo By Investing.com - Investing.com UK
Clearmind gets safety board approval to continue AUD trial - Investing.com Nigeria
Clearmind gets safety board approval to continue AUD trial By Investing.com - Investing.com Canada
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval - Bitget
Clearmind (Nasdaq: CMND) moves CMND-100 alcohol-use trial into higher-dose stage - Stock Titan
Clearmind Medicine IncDSMB approves continuation of Phase I/IIa CMND-100 trial in AUD - marketscreener.com
Alcohol use disorder drug from Clearmind moves to higher-dose testing - Stock Titan
CMND Earnings History & Surprises | EPS & Revenue Results | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
CMND Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
What is Clearmind Medicine Inc.’s book value per shareAnalyst Downgrade & Stepwise Trade Signal Guides - mfd.ru
Is Clearmind Medicine Inc. stock trending bullishAnalyst Downgrade & Precise Entry and Exit Recommendations - mfd.ru
Moonage Media Review: Clearmind's MEAI and GLP-1Are These the Next-Generation Treatment for Weight Loss? - lelezard.com
Market Rankings: How do insiders feel about Clearmind Medicine IncWeekly Stock Report & Growth Focused Entry Reports - baoquankhu1.vn
Clearmind Medicine (CMND) trims second tranche of convertible note deal - Stock Titan
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
What technical signals suggest for Clearmind Medicine Inc. stockJuly 2025 Intraday Action & Real-Time Volume Trigger Notifications - mfd.ru
How Clearmind Medicine Inc. (CWY0) stock trades pre earnings2025 Dividend Review & Expert Curated Trade Ideas - mfd.ru
Is Clearmind Medicine Inc. a turnaround storyWeekly Profit Analysis & Weekly Top Performers Watchlists - mfd.ru
Clearmind reports positive safety data from AUD treatment trial By Investing.com - Investing.com Australia
Clearmind reports positive safety results in AUD drug trial - Investing.com South Africa
Clearmind reports positive safety data from AUD treatment trial - Investing.com South Africa
Clearmind reports positive safety results in AUD drug trial By Investing.com - Investing.com Nigeria
Clearmind Medicine announces additional topline positive safety results reinforcing favorable profile of cmnd-100 in ongoing Phase I/Iia clinical trial - marketscreener.com
Clearmind Medicine stock falls after Phase I/IIa trial safety update By Investing.com - Investing.com South Africa
Clearmind Medicine stock falls after Phase I/IIa trial safety update - Investing.com Nigeria
Clearmind Medicine Announces Additional Positive Safety Topline Data From CMND-100 Study - Nasdaq
Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial - The Manila Times
Clearmind Medicine Inc. Reports Positive Safety Results from Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder - Quiver Quantitative
Polyrizon to develop intranasal formulation of Clearmind’s MEAI drug By Investing.com - Investing.com Nigeria
Clearmind partners with Polyrizon to develop intranasal MEAI formulation By Investing.com - Investing.com Nigeria
Clearmind Medicine (CMND) Stock: Partners With Polyrizon to Advance Intranasal MEAI Therapy - parameter.io
Polyrizon climbs on Clearmind Deal - Baystreet.ca
Finanzdaten der Clearmind Medicine Inc-Aktie (CMND)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):